comparemela.com
  1. Home
  2. Live Updates
  3. Pathos Ai Inc - Breaking News

Latest Breaking News On - Pathos ai inc - Page 6 : comparemela.com

Rain Oncology Goes Private Just Two Years After $120M NASDAQ Debut - Rain Oncology (NASDAQ:RAIN)

Rain Oncology Inc (NASDAQ: RAIN) has agreed to be acquired by Pathos AI Inc.

Avanish vellankiRain oncology incPathos ai incOncology incBrain boardRain oncology

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1 16 in Cash per Share Plus Contingent Value Rights

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1 16 in Cash per Share Plus Contingent Value Rights
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Avanish vellankiExchange commissionRain oncology incDunn crutcherGoodwin procterPathos ai incBrain boardMerger agreementRain oncologyAnnual reportRecommendation statementInvestor relations

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1 16 in Cash per Share Plus Contingent Value Rights

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1 16 in Cash per Share Plus Contingent Value Rights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Avanish vellankiExchange commissionRain oncology incPathos ai incGoodwin procterDunn crutcherOncology entersShare plus contingent valueBrain boardMerger agreementRain oncologyAnnual reportRecommendation statementInvestor relations

Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1 16 in Cash per Share Plus Contingent Value Rights

NEWARK, Calif., Dec. 13, 2023 Rain Oncology Inc. , today announced it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain for $1.16 in cash per share plus.

Avanish vellankiRain oncology incGlobenewswire incExchange commissionGoodwin procterPathos ai incDunn crutcherBrain boardMerger agreementAnnual reportRecommendation statementInvestor relations

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.